Preprint Review Version 1 This version is not peer-reviewed

BRK”ing” Down All We Know About PTK6 in Breast Cancer

Version 1 : Received: 2 August 2018 / Approved: 2 August 2018 / Online: 2 August 2018 (09:58:55 CEST)

How to cite: Yuan, Y.; Ang, H.L.; Lai, X.; Wang, L.; Pandey, V.; Huang, B.B.; Tan, T.Z.; Chong, H.Y.; Ong, P.Z.Y.; Rangappa, K.S.; Arfuso, F.; Tan, K.S.; Basappa; Goh, B.C.; Huang, R.Y.; Sethi, G.; Lobie, P.E.; Kumar, A.P. BRK”ing” Down All We Know About PTK6 in Breast Cancer. Preprints 2018, 2018080044 (doi: 10.20944/preprints201808.0044.v1). Yuan, Y.; Ang, H.L.; Lai, X.; Wang, L.; Pandey, V.; Huang, B.B.; Tan, T.Z.; Chong, H.Y.; Ong, P.Z.Y.; Rangappa, K.S.; Arfuso, F.; Tan, K.S.; Basappa; Goh, B.C.; Huang, R.Y.; Sethi, G.; Lobie, P.E.; Kumar, A.P. BRK”ing” Down All We Know About PTK6 in Breast Cancer. Preprints 2018, 2018080044 (doi: 10.20944/preprints201808.0044.v1).

Abstract

The search for improved therapeutic approaches to breast cancer are still on going. Breast tumor kinase (BRK, also known as PTK6) is one of the targets, it is highly expressed in breast carcinomas while displaying low or no expression in the normal mammary gland, which hints at the oncogenic role of this enzyme in breast cancer. In these twenty years, an increasing number of studies have focused on understanding the cellular roles of BRK in breast cancers. This review outlines the advances made towards understanding the cellular and physiological role of BRK, the molecular and chemical inhibitors and its therapeutic significance in breast cancer.

Subject Areas

breast tumor kinase (BRK); protein tyrosine kinase 6 (PTK6); breast cancer; pathways; therapeutics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.